

SEQUENCE LISTING

<110> Novo Nordisk A/S
 <120> FACTOR VII POLYPEPTIDES WITH INCREASED AFFINITY TO PLATELETS
 <130> 7552.204-WO
 <160> 1
 <170> PatentIn version 3.3
 <210> 1
 <211> 406
 <212> PRT
 <213> Homo sapiens

 <220>
 <221> MOD_RES
 <222> (6)..(6)
 <223> GAMMA-CARBOXYGLUTAMIC ACID

 <220>
 <221> MOD_RES
 <222> (7)..(7)
 <223> GAMMA-CARBOXYGLUTAMIC ACID

 <220>
 <221> MOD_RES
 <222> (14)..(14)
 <223> GAMMA-CARBOXYGLUTAMIC ACID

 <220>
 <221> MOD_RES
 <222> (16)..(16)
 <223> GAMMA-CARBOXYGLUTAMIC ACID

 <220>
 <221> MOD_RES
 <222> (19)..(19)
 <223> GAMMA-CARBOXYGLUTAMIC ACID

 <220>
 <221> MOD_RES
 <222> (20)..(20)
 <223> GAMMA-CARBOXYGLUTAMIC ACID

 <220>
 <221> MOD_RES
 <222> (25)..(25)
 <223> GAMMA-CARBOXYGLUTAMIC ACID

 <220>
 <221> MOD_RES
 <222> (26)..(26)
 <223> GAMMA-CARBOXYGLUTAMIC ACID

<220>
<221> MOD_RES
<222> (29)..(29)
<223> GAMMA-CARBOXYGLUTAMIC ACID

<220>
<221> MOD_RES
<222> (35)..(35)
<223> GAMMA-CARBOXYGLUTAMIC ACID

<400> 1

Ala Asn Ala Phe Leu Glu Glu Leu Arg Pro Gly Ser Leu Glu Arg Glu
1 5 10 15

Cys Lys Glu Glu Gln Cys Ser Phe Glu Glu Ala Arg Glu Ile Phe Lys
20 25 30

Asp Ala Glu Arg Thr Lys Leu Phe Trp Ile Ser Tyr Ser Asp Gly Asp
35 40 45

Gln Cys Ala Ser Ser Pro Cys Gln Asn Gly Gly Ser Cys Lys Asp Gln
50 55 60

Leu Gln Ser Tyr Ile Cys Phe Cys Leu Pro Ala Phe Glu Gly Arg Asn
65 70 75 80

Cys Glu Thr His Lys Asp Asp Gln Leu Ile Cys Val Asn Glu Asn Gly
85 90 95

Gly Cys Glu Gln Tyr Cys Ser Asp His Thr Gly Thr Lys Arg Ser Cys
100 105 110

Arg Cys His Glu Gly Tyr Ser Leu Leu Ala Asp Gly Val Ser Cys Thr
115 120 125

Pro Thr Val Glu Tyr Pro Cys Gly Lys Ile Pro Ile Leu Glu Lys Arg
130 135 140

Asn Ala Ser Lys Pro Gln Gly Arg Ile Val Gly Gly Lys Val Cys Pro
145 150 155 160

Lys Gly Glu Cys Pro Trp Gln Val Leu Leu Leu Val Asn Gly Ala Gln
165 170 175

Leu Cys Gly Gly Thr Leu Ile Asn Thr Ile Trp Val Val Ser Ala Ala
180 185 190

His Cys Phe Asp Lys Ile Lys Asn Trp Arg Asn Leu Ile Ala Val Leu
195 200 205

Gly Glu His Asp Leu Ser Glu His Asp Gly Asp Glu Gln Ser Arg Arg
210 215 220

Val Ala Gln Val Ile Ile Pro Ser Thr Tyr Val Pro Gly Thr Thr Asn
225 230 235 240

His Asp Ile Ala Leu Leu Arg Leu His Gln Pro Val Val Leu Thr Asp
245 250 255

His Val Val Pro Leu Cys Leu Pro Glu Arg Thr Phe Ser Glu Arg Thr
260 265 270

Leu Ala Phe Val Arg Phe Ser Leu Val Ser Gly Trp Gly Gln Leu Leu
275 280 285

Asp Arg Gly Ala Thr Ala Leu Glu Leu Met Val Leu Asn Val Pro Arg
290 295 300

Leu Met Thr Gln Asp Cys Leu Gln Gln Ser Arg Lys Val Gly Asp Ser
305 310 315 320

Pro Asn Ile Thr Glu Tyr Met Phe Cys Ala Gly Tyr Ser Asp Gly Ser
325 330 335

Lys Asp Ser Cys Lys Gly Asp Ser Gly Gly Pro His Ala Thr His Tyr
340 345 350

Arg Gly Thr Trp Tyr Leu Thr Gly Ile Val Ser Trp Gly Gln Gly Cys
355 360 365

Ala Thr Val Gly His Phe Gly Val Tyr Thr Arg Val Ser Gln Tyr Ile
370 375 380

Glu Trp Leu Gln Lys Leu Met Arg Ser Glu Pro Arg Pro Gly Val Leu
385 390 395 400

Leu Arg Ala Pro Phe Pro

